The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

With quarterly revenue up 54% from a year ago, Eli Lilly raised it guidance for the year, with the company now expecting revenue in the range of $63 billion to $63.5 billion ...

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

Eli Lilly ( LLY) is expected to see a multi-fold increase in its earnings during its third quarter earnings, which is scheduled for October 29 after markets close. The pharma giant is expected to ...

In the third quarter, Lilly earned $7.02 per share on an adjusted basis, far above the $5.69 analysts were expecting, ...

By now, your news feed, your dinner table conversations, and your doctor’s office have been flooded with chatter about the ...